To determine if this KOSR-mediated protection could be extended to cancer cells addicted to other oncogenic tyrosine kinases, we tested two Non-Small Cell Lung Cancer (NSCLC) cell lines (HCC827 and H1650) that expressed the exon19-deleted (Δe19) EGFR oncogenic kinase and treated these cells with the EGFR tyrosine kinase inhibitor, gefitinib [41]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.